74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
ESPERION THERAPEUTICS INC
Open
SectorHealthcare
3.02 6.34
Overview
Share price change
24h
Min
2.83
Max
3.36
Income | 28M -13M |
|---|---|
Sales | 17M 82M |
Profit margin | -15.446 |
Employees | 304 |
EBITDA | 37M 16M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +138.62% upside |
Next Earnings | 6 Nov 2025 |
|---|
Market Cap | 239M 534M |
|---|---|
Previous open | -3.32 |
Previous close | 3.02 |
News Sentiment
By Acuity
58%
42%
314 / 371 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
ESPERION THERAPEUTICS INC Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
ESPERION THERAPEUTICS INC Forecast
Price Target
By TipRanks
138.62% upside
12 Months Forecast
Average 6.92 USD 138.62%
High 16 USD
Low 1.6 USD
Based on 5 Wall Street analysts offering 12 month price targets forESPERION THERAPEUTICS INC - Dist in the last 3 months.
Sentiment
By Acuity
314 / 371 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About ESPERION THERAPEUTICS INC
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Live chat